PharmaMar initiates first human clinical trial of a new molecule, PM534, for cancer patients

This new compound of marine origin is the result of research and development by PharmaMar’s R&D team. PharmaMar (MSE: PHM) has announced today the initiation of a new Phase I clinical trial with PM534, a novel marine-derived anti-tumor compound resulting from the Company’s research program for the treatment of solid tumors. PM534 has been tested in the laboratory, both in cell cultures (in vitro) and in animals (in vivo). In both cases, PM534 showed relevant antitumor activity in a wide variety of tumor types, including those with resistance to other chemotherapies. The objectives of this first human clinical trial are to find the recommended dose and, in turn, to evaluate the safety and efficacy profile. The trial will be conducted in patients with advanced solid tumors who will be administered the drug intravenously.

The release as fetched from its publisher. pharmamar.com ↗